Ceftiofur
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Overview
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987.[1] It is marketed by pharmaceutical company Pfizer as Excede.[2]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against Gram-positive and Gram-negative bacteria. E. coli strains resistant to ceftiofur have been reported.[3]
References
References
- ↑ Yancey RJ, Kinney ML, Roberts BJ, Goodenough KR, Hamel JC, Ford CW (1987). “Ceftiofur sodium, a broad-spectrum cephalosporin: evaluation in vitro and in vivo in mice”. Am. J. Vet. Res. 48 (7): 1050–3. PMID 3631686.
- ↑ “Pfizer Animal ealth Dairy Information on Products and Solutions”. Retrieved 2007-11-20.
- ↑ Donaldson SC, Straley BA, Hegde NV, Sawant AA, DebRoy C, Jayarao BM (2006). “Molecular epidemiology of ceftiofur-resistant Escherichia coli isolates from dairy calves”. Appl. Environ. Microbiol. 72 (6): 3940–8. doi:10.1128/AEM.02770-05. PMID 16751500.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH